Tags : Anemia

Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for

Shots: The global program includes two P-III studies assessing vadadustat (PO) vs darbepoetin alfa (inj.) in a ratio (1:1) in incident dialysis patients (Correction/Conversion) and prevalent dialysis patients (Conversion), in ~3,923 adult patients on dialysis with anemia due to CKD The presentation expands on previously reported positive data showing vadadustat achieved clear and consistent results […]Read More

Astellas Reports Results of Roxadustat in P-III DOLOMITES Study to

Shots: The P-III study involves assessing of Roxadustat (N=323) vs darbepoetin alfa (N=293) evaluating its safety and efficacy in (N=616) adult anemia patients with stage 3–5 chronic kidney disease (CKD) The study meet its 1EPs & 2EPs also demonstrated superiority, showing correction of hemoglobin levels during the first 24 wks. (89.5% vs 78.0%), decrease in […]Read More

ViewPoints Interview: AstraZeneca’s Global Medicine Leader John Houghton Shares Insights

AstraZeneca presented P-III data of Roxadustat along with unprecedented 41 abstracts from its renal portfolio at American Society of Nephrology Kidney Week 2019, demonstrating its commitment to advancing the care of Chronic Kidney Diseases (CKD) and its complications, affecting millions of people across the globe. On Nov 12, 2019 in an interview with PharmaShots, John […]Read More

AstraZeneca and FibroGen’s Roxadustat Receive NMPA’s Approval for the Treatment

Shots: The NMPA’s approval is based on P-III study result assessing Roxadustat vs PBO in non-dialysis-dependent (NDD) patients with CKD demonstrating improvement in hemoglobin levels with a mean change of (1.9 g/dL vs -0.4 g/dL) on 7-9wks. treatment In 2013, AstraZeneca and FibroGen collaborated for the development & commercialization of Roxadustat in China. The NMPA’s […]Read More

Pfizer’s Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia

Shots: The approval is based on non-inferiority data demonstrating biosimilarity between Retacrit and the reference product, Epogen & Procrit In May, 2016 Pfizer and Vifor Pharma collaborated for the commercialization of retacrit in certain therapeutic areas Retacrit (epoetin alfa) a biosimilar to Epogen & Procrit, is an erythropoiesis-stimulating agent (ESA) indicated for anemia and reduction […]Read More